Drug Trial Radar · NCT00289029
A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography
Last checked: Nov 19, 2026Latest source record: Aug 18, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Jul 2005
Primary completion
Not stated
Study completion Jun 2006
Sponsor
- Lead sponsor
- Bracco Diagnostics, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 9, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficiency undergoing cardiac angiography. Serum creatinine will be measured before and up to 48-72 hours after the administration of the contrast agent to evaluate renal function.
Conditions
- CIN
Interventions
Iopamidol 370 mgI/mLDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Increase in SCr at 48-72 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bracco Diagnostics, Inc
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.